Lv65
1670 积分 2024-06-26 加入
[Response characteristics of tislelizumab combined with chemotherapy in first-line treatment of locally advanced or metastatic non-squamous non-small cell lung cancer]
16天前
已完结
The rebirth of epitope-based patent claims
28天前
已完结
Determinants of successful minimally invasive surgery (MIS) for resectable non-small cell lung cancer (NSCLC) after neoadjuvant therapy
29天前
已完结
Targeting neoantigens to augment antitumour immunity
1个月前
已完结
Targeting neoantigens to augment antitumour immunity
1个月前
已完结
Non-small-cell lung cancer
1个月前
已完结
Stereotactic body radiotherapy with sequential tislelizumab and chemotherapy as neoadjuvant therapy in patients with resectable non-small-cell lung cancer in China (SACTION01): a single-arm, single-centre, phase 2 trial
1个月前
已完结
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
1个月前
已完结
Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial
1个月前
已完结
Can We Offset Local Recurrence in Locally Advanced Non–Small Cell Lung Cancer? The Merry-Go-Round of Radiation Dose Escalation and Stubborn Outcomes
1个月前
已完结
皖公网安备34019202002308
